Campos-Barrera E, Tello-Mendoza T, Joya-Galeana J, Vergara-López A, Ortega-Gómez MR, Guillén-González MÁ

Language: Spanish
References: 13
Page: 78-83
PDF size: 200.48 Kb.

ABSTRACT

Background: Acromegaly has a reported prevalence of 40 to 60 cases per million, yet no official figures have been reported in Mexico. Objective: To determine demographic, clinical and biochemical characteristics as well as comorbilities and surgical results in our patients with acromegaly. Materials and methods: Medical files from patients with acromegaly attending our Clinic between 1983 and 2009 were reviewed. The information analyzed included age, gender, symptoms, hormonal levels, type of treatment, biochemical cure and comorbilities. Results: Mean age at diagnosis was 43 ± 11 years. Diagnosis was delayed by a median of 3 years. 57% of patients were female. Basal GH level was 11 ng/mL (0.8 -74 ng/mL) and mean IGF-1 612 ± 272 ng/mL. Median post glucose GH was 8.5 ng/mL (0.8 - 60 ng/mL). 24% of patients achieved biochemical cure after surgery (19% in micro-and 25% in macroadenomas). 72% required medical treatment after surgery with somatostatin analogues (SA), while 43% received radiotherapy (RT). Diabetes was present in 27%, hypertension in 52%, coronary arterial disease in 4.7% and osteoporosis in 5.7%. The RR for the development of diabetes was greater among patients with macroadenoma than in those with microadenomas (3.74, 95% CI 1.2 - 11.6, p = 0.023). Conclusions: Clinical and biochemical characteristics of our patients are similar to those reported previously. Our surgical cure rate is considerably lower and a significant proportion requires adjunctive treatment with either SA or RT.

REFERENCES

1. Bengtsson BA, Eden S, Ernest I, Oden A, Sjögren B. Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnoses between 1955 and 1984. Acta Med Scand 1988; 223: 327-335.

2. Colao A, Ferrone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004; 25: 102-152.

3. Mercado M, Espinosa de los Monteros AL, Sosa E, Cheng S, Mendoza V, Hernández I, Sandoval C, Guinto G, Molina M. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 2004; 63: 293-299.

4. Navarro JDN. Acromegaly. Clin Endocrinol 1987; 26: 481-512.

5. Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibansky A. Extensive clinical experience: changing patterns in diagnosis and therapy or acromegaly over two decades. J Clin Endocrinol Metab 2008; 93: 2035-2041.

6. Arya KR, Krishna K, Chadda M. Skin manifestations of acromegaly. Indian J Dermatol Venereol Leprol 1997; 63: 178-180.

7. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Medicine 1994: 73: 233-240.

8. Mestrón A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the spanish acromegaly registry. Eur J Endocrinol 2004: 151: 439-446.

9. Sheaves R, Jenkins P, Blackburn P et al. Outcome of transsphenoidal surgery using strict criteria for surgical cure. Clin Endocrinol 1996; 45: 407-413.

10. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up in 115 patients who underwent trans-sphenoidal surgery for acromegaly. J Neurosurg 1998; 89: 353-358.

11. Kreutzer J, Vance ML, Lopes MB, Laws ER. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001; 86: 4072-4077.

12. Arellano S, Aguilar P, Domínguez B, Espinosa de los Monteros AL, González VB, Sosa E, Mercado M et al. Segundo Consenso Nacional de Acromegalia: recomendaciones para su diagnóstico, tratamiento y seguimiento. Revista de Endocrinología y Nutrición 2007; 15(supl 1): s7-s16.

13. Melmed S, Colao A, Barkan M, Molitch M, Grossman AB, Kleinberg D et al. Guidelines for acromegaly management: an update, J Clin Endocrinol Metab 2009; 94: 1509-1517.